FDA approves first targeted therapy for metastatic bladder cancer - FDA Press Releases

The FDA granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy.

from Food and Drug Administration--Press Releases http://bit.ly/2UTpwvk
via IFTTT